Skip to main content
Top
Published in: Arthritis Research & Therapy 5/2009

Open Access 01-10-2009 | Research article

Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations

Authors: Pravitt Gourh, Frank C Arnett, Shervin Assassi, Filemon K Tan, Mei Huang, Laura Diekman, Maureen D Mayes, John D Reveille, Sandeep K Agarwal

Published in: Arthritis Research & Therapy | Issue 5/2009

Login to get access

Abstract

Introduction

Systemic sclerosis (SSc) (scleroderma) is a complex autoimmune disease that clinically manifests as progressive fibrosis of the skin and internal organs. Anti-centromere antibodies (ACAs), anti-topoisomerase antibodies (ATAs), and anti-RNA polymerase III antibodies (ARAs) are three mutually exclusive SSc-associated autoantibodies that correlate with distinct clinical subsets characterized by extent of cutaneous involvement and pattern of organ involvement. The current report sought to determine whether plasma cytokine profiles differ in SSc patients grouped according to these SSc-associated autoantibody subsets.

Methods

Plasma from 444 SSc patients and 216 healthy controls was obtained from the Scleroderma Family Registry and University of Texas Rheumatology Division. Patients were classified according to the presence of ACAs, ATAs, ARAs, or none of the above (antibody-negative). Levels of 13 cytokines were determined using multiplex assays.

Results

Compared with females, healthy control males had higher plasma levels of IL-2 (P = 0.008), IL-5 (P = 0.01) and IL-8 (P = 0.01). In addition, in controls, IL-6 (P = 0.02) and IL-17 (P = 0.01) levels increased with advancing age. After adjusting for age and gender, SSc patients had higher circulating levels of TNFα (P < 0.0001), IL-6 (P < 0.0001), and IFNγ (P = 0.05) and lower IL-17 (P = 0.0005) and IL-23 (P = 0.014). Additional analyses demonstrated that disease duration also influenced these cytokine profiles. IL-6 was elevated in ATA-positive and ARA-positive patients, but not in ACA-positive patients. IL-8 was uniquely increased in the ATA-positive subset while both ATA-positive and ACA-positive subsets had elevated IFNγ and IL-10. IL-5 was only significantly increased in the ACA-positive subset. Lastly, patients with interstitial lung disease had elevated IL-6 and patients with pulmonary hypertension had elevated IL-6 and IL-13.

Conclusions

Plasma cytokine profiles differ in SSc patients based on the presence of SSc-associated autoantibodies. Plasma cytokine profiles in SSc patients may also be affected by disease duration and the pattern of internal organ involvement.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fleischmajer R, Perlish JS, Reeves JR: Cellular infiltrates in scleroderma skin. Arthritis Rheum. 1977, 20: 975-984. 10.1002/art.1780200410.CrossRefPubMed Fleischmajer R, Perlish JS, Reeves JR: Cellular infiltrates in scleroderma skin. Arthritis Rheum. 1977, 20: 975-984. 10.1002/art.1780200410.CrossRefPubMed
2.
go back to reference Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, Jin L, Arnett FC: Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford). 2006, 45: 694-702. 10.1093/rheumatology/kei244.CrossRef Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, Jin L, Arnett FC: Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford). 2006, 45: 694-702. 10.1093/rheumatology/kei244.CrossRef
3.
go back to reference Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, Pupilli C, Pizzolo G, Maggi E, Romagnani S: Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol. 1997, 151: 1751-1758.PubMedCentralPubMed Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, Pupilli C, Pizzolo G, Maggi E, Romagnani S: Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol. 1997, 151: 1751-1758.PubMedCentralPubMed
4.
go back to reference Needleman BW, Wigley FM, Stair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum. 1992, 35: 67-72. 10.1002/art.1780350111.CrossRefPubMed Needleman BW, Wigley FM, Stair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum. 1992, 35: 67-72. 10.1002/art.1780350111.CrossRefPubMed
5.
go back to reference Molteni M, Della BS, Mascagni B, Bazzi S, Zulian C, Compasso S, Lessi M, Scorza R: Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol. 1999, 116: 164-168. 10.1046/j.1365-2249.1999.00842.x.PubMedCentralCrossRefPubMed Molteni M, Della BS, Mascagni B, Bazzi S, Zulian C, Compasso S, Lessi M, Scorza R: Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol. 1999, 116: 164-168. 10.1046/j.1365-2249.1999.00842.x.PubMedCentralCrossRefPubMed
6.
go back to reference Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K: Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol. 1998, 25: 308-313.PubMed Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K: Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol. 1998, 25: 308-313.PubMed
7.
go back to reference Hasegawa M, Sato S, Ihn H, Takehara K: Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford). 1999, 38: 612-617. 10.1093/rheumatology/38.7.612.CrossRef Hasegawa M, Sato S, Ihn H, Takehara K: Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford). 1999, 38: 612-617. 10.1093/rheumatology/38.7.612.CrossRef
8.
go back to reference Sato S, Hasegawa M, Takehara K: Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci. 2001, 27: 140-146. 10.1016/S0923-1811(01)00128-1.CrossRefPubMed Sato S, Hasegawa M, Takehara K: Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci. 2001, 27: 140-146. 10.1016/S0923-1811(01)00128-1.CrossRefPubMed
9.
go back to reference Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol. 1997, 24: 663-665.PubMed Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol. 1997, 24: 663-665.PubMed
10.
go back to reference Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997, 24: 328-332.PubMed Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997, 24: 328-332.PubMed
11.
go back to reference Sato S, Hanakawa H, Hasegawa M, Nagaoka T, Hamaguchi Y, Nishijima C, Komatsu K, Hirata A, Takehara K: Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol. 2000, 27: 2838-2842.PubMed Sato S, Hanakawa H, Hasegawa M, Nagaoka T, Hamaguchi Y, Nishijima C, Komatsu K, Hirata A, Takehara K: Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol. 2000, 27: 2838-2842.PubMed
12.
go back to reference Arnett FC, Reveille JD, Valdez BC: Autoantibodies to a nucleolar RNA helicase protein in patients with connective tissue diseases. Arthritis Rheum. 1997, 40: 1487-1492. 10.1002/art.1780401003.CrossRefPubMed Arnett FC, Reveille JD, Valdez BC: Autoantibodies to a nucleolar RNA helicase protein in patients with connective tissue diseases. Arthritis Rheum. 1997, 40: 1487-1492. 10.1002/art.1780401003.CrossRefPubMed
13.
go back to reference Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, LeRoy EC, Fritzler MJ: Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum. 1996, 39: 1151-1160. 10.1002/art.1780390712.CrossRefPubMed Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, LeRoy EC, Fritzler MJ: Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum. 1996, 39: 1151-1160. 10.1002/art.1780390712.CrossRefPubMed
14.
go back to reference Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, Fritzler MJ, Ahn C, Arnett FC: Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001, 30: 332-346. 10.1053/sarh.2001.20268.CrossRefPubMed Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, Fritzler MJ, Ahn C, Arnett FC: Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001, 30: 332-346. 10.1053/sarh.2001.20268.CrossRefPubMed
15.
go back to reference Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA: Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007, 34: 104-109.PubMed Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA: Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007, 34: 104-109.PubMed
16.
go back to reference Wu SP, Leng L, Feng Z, Liu N, Zhao H, McDonald C, Lee A, Arnett FC, Gregersen PK, Mayes MD, Bucala R: Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum. 2006, 54: 3661-3669. 10.1002/art.22179.CrossRefPubMed Wu SP, Leng L, Feng Z, Liu N, Zhao H, McDonald C, Lee A, Arnett FC, Gregersen PK, Mayes MD, Bucala R: Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum. 2006, 54: 3661-3669. 10.1002/art.22179.CrossRefPubMed
17.
go back to reference Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980, 23: 581-590. 10.1002/art.1780230510. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980, 23: 581-590. 10.1002/art.1780230510.
18.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988, 15: 202-205.PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988, 15: 202-205.PubMed
19.
go back to reference Chowdhury F, Williams A, Johnson P: Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods. 2009, 340: 55-64. 10.1016/j.jim.2008.10.002.CrossRefPubMed Chowdhury F, Williams A, Johnson P: Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods. 2009, 340: 55-64. 10.1016/j.jim.2008.10.002.CrossRefPubMed
20.
go back to reference Olivier J, Johnson WD, Marshall GD: The logarithmic transformation and the geometric mean in reporting experimental IgE results: what are they and when and why to use them?. Ann Allergy Asthma Immunol. 2008, 100: 333-337.CrossRefPubMed Olivier J, Johnson WD, Marshall GD: The logarithmic transformation and the geometric mean in reporting experimental IgE results: what are they and when and why to use them?. Ann Allergy Asthma Immunol. 2008, 100: 333-337.CrossRefPubMed
21.
go back to reference Bombardieri S, Medsger TA, Silman AJ, Valentini G: The assessment of the patient with systemic sclerosis. Introduction. Clin Exp Rheumatol. 2003, 21: S2-S4.PubMed Bombardieri S, Medsger TA, Silman AJ, Valentini G: The assessment of the patient with systemic sclerosis. Introduction. Clin Exp Rheumatol. 2003, 21: S2-S4.PubMed
22.
23.
go back to reference Giacomelli R, Cipriani P, Lattanzio R, Di FM, Locanto M, Parzanese I, Passacantando A, Ciocci A, Tonietti G: Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol. 1997, 108: 42-46. 10.1046/j.1365-2249.1997.d01-991.x.PubMedCentralCrossRefPubMed Giacomelli R, Cipriani P, Lattanzio R, Di FM, Locanto M, Parzanese I, Passacantando A, Ciocci A, Tonietti G: Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol. 1997, 108: 42-46. 10.1046/j.1365-2249.1997.d01-991.x.PubMedCentralCrossRefPubMed
24.
go back to reference McGaha TL, Bona CA: Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma. Autoimmun Rev. 2002, 1: 174-181. 10.1016/S1568-9972(02)00027-7.CrossRefPubMed McGaha TL, Bona CA: Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma. Autoimmun Rev. 2002, 1: 174-181. 10.1016/S1568-9972(02)00027-7.CrossRefPubMed
25.
go back to reference Valentini G, Baroni A, Esposito K, Naclerio C, Buommino E, Farzati A, Cuomo G, Farzati B: Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol. 2001, 21: 210-217. 10.1023/A:1011024313525.CrossRefPubMed Valentini G, Baroni A, Esposito K, Naclerio C, Buommino E, Farzati A, Cuomo G, Farzati B: Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol. 2001, 21: 210-217. 10.1023/A:1011024313525.CrossRefPubMed
26.
go back to reference Giacomelli R, Cipriani P, Fulminis A, Barattelli G, Matucci-Cerinic M, D'Alo S, Cifone G, Tonietti G: Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol. 2001, 125: 310-315. 10.1046/j.1365-2249.2001.01603.x.PubMedCentralCrossRefPubMed Giacomelli R, Cipriani P, Fulminis A, Barattelli G, Matucci-Cerinic M, D'Alo S, Cifone G, Tonietti G: Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol. 2001, 125: 310-315. 10.1046/j.1365-2249.2001.01603.x.PubMedCentralCrossRefPubMed
27.
go back to reference Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003, 421: 744-748. 10.1038/nature01355.CrossRefPubMed Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003, 421: 744-748. 10.1038/nature01355.CrossRefPubMed
28.
go back to reference Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006, 441: 235-238. 10.1038/nature04753.CrossRefPubMed Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006, 441: 235-238. 10.1038/nature04753.CrossRefPubMed
29.
go back to reference Bettelli E, Korn T, Kuchroo VK: Th17: the third member of the effector T cell trilogy. Curr Opin Immunol. 2007, 19: 652-657. 10.1016/j.coi.2007.07.020.PubMedCentralCrossRefPubMed Bettelli E, Korn T, Kuchroo VK: Th17: the third member of the effector T cell trilogy. Curr Opin Immunol. 2007, 19: 652-657. 10.1016/j.coi.2007.07.020.PubMedCentralCrossRefPubMed
30.
go back to reference Murata M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Komura K, Sato S: Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?. J Dermatol Sci. 2008, 50: 240-242. 10.1016/j.jdermsci.2008.01.001.CrossRefPubMed Murata M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Komura K, Sato S: Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?. J Dermatol Sci. 2008, 50: 240-242. 10.1016/j.jdermsci.2008.01.001.CrossRefPubMed
31.
go back to reference Komura K, Fujimoto M, Hasegawa M, Ogawa F, Hara T, Muroi E, Takehara K, Sato S: Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol. 2008, 35: 120-125. 10.3899/jrheum.080120.CrossRefPubMed Komura K, Fujimoto M, Hasegawa M, Ogawa F, Hara T, Muroi E, Takehara K, Sato S: Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol. 2008, 35: 120-125. 10.3899/jrheum.080120.CrossRefPubMed
32.
go back to reference Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, Fritzler MJ, Ahn C, Arnett FC: Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001, 30: 332-346. 10.1053/sarh.2001.20268.CrossRefPubMed Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, Fritzler MJ, Ahn C, Arnett FC: Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001, 30: 332-346. 10.1053/sarh.2001.20268.CrossRefPubMed
Metadata
Title
Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations
Authors
Pravitt Gourh
Frank C Arnett
Shervin Assassi
Filemon K Tan
Mei Huang
Laura Diekman
Maureen D Mayes
John D Reveille
Sandeep K Agarwal
Publication date
01-10-2009
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2009
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2821

Other articles of this Issue 5/2009

Arthritis Research & Therapy 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.